Business
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
- 2Q19 Net Sales Grew to $83.2 Million, a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million SAN DIEGO--(BUSINESS
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- 2Q19 Net Sales Grew to $83.2 Million, a 46% Increase Over 2Q18\n\n\n- 2019 Net Sales Guidance Increased to $320 Million to $330 Million\n\n SAN DIEGO--(BUSINESS WIRE)--\nACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2019.\n\n\n“Continued execution of our commercial initiatives led to strong quarterly performance for NUPLAZID and a significant increase in our sales guidance for the full year,” said Steve Davis, ACADIA’s Chief Executive Officer. “This quarter we initiated a Phase 3 program for pimavanserin in major depressive disorder and in the fourth quarter we plan to initiate a Phase 3 program for trofinetide in Rett syndrome. Additionally for pimavanserin, we expect to announce top-line results from our schizophrenia negative symptoms ADVANCE study around year-end and we expect to announce top-line results from our dementia-related psychosis HARMONY study in the second half of 2020, with an interim read in the second half of this year.”\n\n\nRecent Highlights\n\n\n\nAnnounced top-line results from the Phase 3 ENHANCE study of pimavanserin for adjunctive treatment in patients with schizophrenia. In the study, adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however the results did not achieve statistical significance on the primary endpoint, the Positive and Negative Syndrome Scale (PANSS) total score (p=0.0940). Significant improvements were observed on the secondary endpoint of PANSS negative symptoms scale sub-score (unadjusted p=0.0474). Additional details from the study are included in the press release issued by the Company on July 22, 2019.\n\n\nPresented positive Phase 2 CLARITY results for pimavanserin as an adjunctive treatment in major depressive disorder at the 2019 American Psychiatric Association Annual Meeting in May 2019.\n\n\nInitiated the international Phase 3 CLARITY-3 study with pimavanserin for adjunctive treatment in patients with major depressive disorder in July 2019.\n\n\nAnnounced in June 2019, alongside the Michael J. Fox Foundation for Parkinson’s Research, the launch of “Parkinson’s IQ ...